27P Chemotherapy (chemo) rechallenge in patients (pts) with EGFR-mutated (EGFRm) advanced NSCLC who discontinued 1L osimertinib (osi) + platinum–pemetrexed (plat–pem) due to progression (PD): FLAURA2 exploratory analysis

adverse events (AEs) of any grade were anemia (18.3%), urinary tract infection (11.7%), and decreased neutrophil count (10.0%).No new safety signals were identified compared with the established profiles of each individual drug. Conclusions:The all-oral combination of aumolertinib and etoposide demonstrated promising antitumor activity and a manageable safety profile in treatment-naive EGFR-mutated NSCLC.This regimen offers a potential convenient, outpatient-based therapeutic strategy worthy of further validation.Clinical trial identification: NCT06463171.

Authors

Institutions

Publication Details

Journal
ESMO Open
Published
2026-03-17
DOI
https://doi.org/10.1016/j.esmoop.2026.106334
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

27P Chemotherapy (chemo) rechallenge in patients (pts) with EGFR-mutated (EGFRm) advanced NSCLC who discontinued 1L osimertinib (osi) + platinum–pemetrexed (plat–pem) due to progression (PD): FLAURA2 exploratory analysis

K.K. Laktionov, Igor Andrašina, Muna Albayaty, K. Barrett et al.
ESMO Open
Lung Cancer Treatments and Mutations
article

27P Chemotherapy (chemo) rechallenge in patients (pts) with EGFR-mutated (EGFRm) advanced NSCLC who discontinued 1L osimertinib (osi) + platinum–pemetrexed (plat–pem) due to progression (PD): FLAURA2 exploratory analysis

K.K. Laktionov, Igor Andrašina, Muna Albayaty, K. Barrett, G.D.J. Pinto, Niki Lama, T.V. Tran, K. Kobayashi, D. Planchard, L. Jiang, T.M. Kim, X. Quantin, A.L. Evans, S. Sugawara, P.A. Jänne, S. Lucien Geater, C.I. Rojas, Y. Fan, C. Escriu, J.C-H. Yang
article en

Abstract

adverse events (AEs) of any grade were anemia (18.3%), urinary tract infection (11.7%), and decreased neutrophil count (10.0%).No new safety signals were identified compared with the established profiles of each individual drug. Conclusions:The all-oral combination of aumolertinib and etoposide demonstrated promising antitumor activity and a manageable safety profile in treatment-naive EGFR-mutated NSCLC.This regimen offers a potential convenient, outpatient-based therapeutic strategy worthy of further validation.Clinical trial identification: NCT06463171.

ESMO OpenVol. 11
Prince of Songkla University (TH), Inserm (FR), Shanghai Jiao Tong University (CN), Université Paris-Saclay (FR), Institut Gustave Roussy (FR), Shanghai Chest Hospital (CN), Seoul National University Hospital (KR), Clatterbridge Cancer Centre NHS Foundation Trust (GB), Hospital de Câncer de Barretos (BR), Národný Onkologický Ústav (SK), Zhejiang Cancer Hospital (CN), University Medical Center HCMC (VN), AstraZeneca (Singapore) (SG), Dana-Farber Cancer Institute (US), Instituto Nacional de Enfermedades Neoplásicas (PE), National Taiwan University Hospital (TW), Institut de Recherche en Cancérologie de Montpellier (FR), National Medical Research Center of Cardiology (RU), AstraZeneca (Spain) (ES), Sendai Kousei Hospital (JP), Saitama Medical University (JP)
Openalex Percentile: Top 20%
Lung Cancer Treatments and Mutations
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.